A phase 1 trial of AP30663, a K Ca 2 channel inhibitor in development for conversion of atrial fibrillation.

Autor: Yfanti C; Centre for Human Drug Research, Leiden, the Netherlands., Vestbjerg B; Acesion Pharma ApS, Copenhagen, Denmark., Van't Westende J; Centre for Human Drug Research, Leiden, the Netherlands., Edvardsson N; Acesion Pharma ApS, Copenhagen, Denmark.; Department of Molecular and Clinical Medicine/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Monfort LM; Department of Biomedical Sciences, University of Copenhagen, Denmark., Olesen MS; Department of Biomedical Sciences, University of Copenhagen, Denmark., Bentzen BH; Acesion Pharma ApS, Copenhagen, Denmark.; Department of Biomedical Sciences, University of Copenhagen, Denmark., Grunnet M; Acesion Pharma ApS, Copenhagen, Denmark., Eveleens Maarse BC; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., Diness JG; Acesion Pharma ApS, Copenhagen, Denmark., Kemme MJB; Cardiology department, Amsterdam UMC, Amsterdam, the Netherlands., Sørensen U; Acesion Pharma ApS, Copenhagen, Denmark., Moerland M; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., van Esdonk MJ; Centre for Human Drug Research, Leiden, the Netherlands., Klaassen ES; Centre for Human Drug Research, Leiden, the Netherlands., Gal P; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., Holst AG; Acesion Pharma ApS, Copenhagen, Denmark.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Apr; Vol. 90 (4), pp. 1027-1035. Date of Electronic Publication: 2024 Jan 08.